Table 4.
Response rate and survival (failure-free, and overall) according to the need for dose reduction and/or interruption
| Stage | Dose Reduction/Interruption |
N | % MCyR |
% CCyR |
2-year FFS % (median, months |
2-year OS % (median, months) |
|---|---|---|---|---|---|---|
| ECP | Yes | 50 | 94 | 92 | 72 (NR) | 100 (NR) |
| No | 48 | 88 | 88 | 83 (NR) | 100 (NR) | |
| p | 0.56 | 0.09 | 0.03 | 0.73 | ||
| LCP | Yes | 58 | 59 | 52 | 46 (20) | 93 (NR) |
| No | 17 | 53 | 53 | 33 (11) | 59 (29) | |
| p | 0.45 | 0.92 | 0.21 | 0.02 | ||
| AP | Yes | 39 | 49 | 28 | 19 (9) | 54 (29) |
| No | 20 | 20 | 20 | 17 (3) | 58 (27) | |
| p | 0.19 | 0.79 | 0.39 | 0.84 | ||
| BP/Ph+ ALL | Yes | 29 | 38 | 26 | 17 (4.5) | 26 (7) |
| No | 19 | 32 | 26 | 0 (3) | 26 (7) | |
| p | 0.71 | 0.87 | 0.35 | 0.7 |
MCyR, major cytogenetic response; CCyR, complete cytogenetic response; FFS, failure-free survival; OS, overall survival; ECP, early chronic phase; LCP, late chronic phase; AP, acute phase; BP/Ph+ ALL, blast phase/ Philadelphia positive acute lymphoblastic leukaemia; NR, not reached.